Clinical Trial

Disease: Relapsed/Refractory Multiple Myeloma, (NCT05722418)

Disease info:

Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the centre of most bones. Multiple myeloma is characterised by abnormalities in a type of white blood cell known as the plasma cells. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumours within the bone, causing bone pain and an increased risk of fractures.

Frequency:
Multiple myeloma occurs in approximately 4 per 100,000 people per year; there are currently about 100,000 affected individuals in the United States.
Official title:
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Who:

Contact

Name: DeShaun Noakes, MS

Phone: 7605334023 

Email: dnoakes@cariboubio.com

Sponsor:

Caribou Biosciences

Partners:
Locations:

United States, New York

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Contact: Adriana Rossi, MD    917-828-3905    adriana.rossi@mssm.edu   

Principal Investigator: Adriana Rossi, MD         

United States, Ohio

Oncology Hematology Care, Inc

Cincinnati, Ohio, United States, 45236

Contact: Doug Hart       douglas.hart@usoncology.com   

Principal Investigator: James Essell, MD         

United States, Tennessee

Sarah Cannon Research Institute

Nashville, Tennessee, United States, 37203

Contact: Jesus Berdeja, MD    844-482-4812    asksarah@sarahcannon.com   

Principal Investigator: Jesus Berdeja, MD         

 

Study start:
Feb. 6, 2023
Enrollment:
50 participants
Gene editing method:
Cas12a chRDNA (CRISPR hybrid RNA-DNA)
Type of edit:
Gene knock-out, gene knock-in
Gene:
B-cell maturation antigen (BCMA) T Cell Receptor (TCR) beta-2 microglobulin (B2M)
Delivery method:
Adeno-associated virus (AAV)
Trial link:
https://www.clinicaltrials.gov/ct2/show/NCT05722418
Safety updates:

(4-4-2023) Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

(29-3-2023) Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

(21-11-2022) Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Other links:

LinkCRISPR Clinical Trial Updates From Caribou Biosciences (April 2023)

Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

Last updated: Jun. 5, 2023
close
Search CRISPR Medicine